Clinical trial
An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute…
NCT00412620 · Abbott, Industry · Terminated
Key facts
| NCT number | NCT00412620 |
|---|---|
| Title | An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia |
| Official title | Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia |
| Lead sponsor | Abbott, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | ABT-925, Placebo |
| Enrollment | 156 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Dec 18, 2006 |
| Last update posted | Apr 27, 2011 |
| Countries | Argentina, Mexico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: